No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
Abelmoschus manihot |
- |
- |
- |
- |
1件: 66 |
2 |
Ace inhibitor |
- |
- |
- |
- |
1件: 66 |
3 |
Ace inhibitor or angiotensin receptor antagonist |
Angiotensin ii |
D00150, D02014 |
2件: AGTR1, AGTR2 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 66 |
4 |
Ace/arb |
- |
- |
- |
- |
1件: 66 |
5 |
Acei |
- |
- |
- |
- |
2件: 66, 224 |
6 |
Acei/arb and corticosteroids |
- |
- |
- |
- |
1件: 66 |
7 |
Acteoside |
Acteoside |
- |
- |
- |
1件: 66 |
8 |
Acth |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
5件: 13, 66, 145, 193, 222 |
9 |
Acth (acthar) gel |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 66 |
10 |
Acthar 80 unit injection |
- |
- |
- |
- |
1件: 66 |
11 |
Aliskiren |
Aliskiren |
D03208 |
1件: REN |
2件: Renin secretion, Renin-angiotensin system |
3件: 66, 167, 222 |
12 |
Allopurinol |
Allopurinol |
D00224 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
6件: 6, 46, 57, 66, 96, 97 |
13 |
Angiotensin |
Angiotensin ii |
D00150, D02014 |
2件: AGTR1, AGTR2 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
7件: 17, 19, 46, 66, 86, 222, 224 |
14 |
Angiotensin blockade |
Angiotensin ii |
D00150, D02014 |
2件: AGTR1, AGTR2 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 66 |
15 |
Angiotensin ii |
Angiotensin ii |
D00150, D02014 |
2件: AGTR1, AGTR2 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 66, 222 |
16 |
Apl-2 |
- |
- |
- |
- |
5件: 61, 62, 66, 222, 223 |
17 |
Atacicept |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
4件: 13, 46, 49, 66 |
18 |
Atacicept 150 mg |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
3件: 13, 49, 66 |
19 |
Atacicept 25 mg |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
2件: 13, 66 |
20 |
Atacicept 75 mg |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
3件: 13, 49, 66 |
21 |
Atacicept150mg |
- |
- |
- |
- |
1件: 66 |
22 |
Atacicept25mg |
- |
- |
- |
- |
1件: 66 |
23 |
Atacicept75mg |
- |
- |
- |
- |
1件: 66 |
24 |
Atg-f |
- |
- |
- |
- |
1件: 66 |
25 |
Azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
18件: 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
26 |
Bardoxolone |
Bardoxolone |
D09584 |
- |
- |
7件: 66, 67, 84, 85, 86, 218, 222 |
27 |
Bardoxolone methyl |
Bardoxolone methyl |
D09585 |
- |
- |
7件: 66, 67, 84, 85, 86, 218, 222 |
28 |
Bardoxolone methyl capsules |
Bardoxolone methyl |
D09585 |
- |
- |
4件: 66, 67, 86, 222 |
29 |
Betaloc |
Metoprolol |
D00601, D02358, D05011 |
1件: ADRB1 |
10件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 66 |
30 |
Bion-1301 multiple doses |
- |
- |
- |
- |
1件: 66 |
31 |
Bion-1301 single dose |
- |
- |
- |
- |
1件: 66 |
32 |
Blisibimod |
Blisibimod |
D10311 |
- |
- |
5件: 43, 44, 49, 63, 66 |
33 |
Blood sample |
- |
- |
- |
- |
12件: 8, 13, 46, 49, 51, 53, 61, 66, 97, 274, 288, 299 |
34 |
Bortezomib |
Bortezomib |
D03150 |
1件: PSMB5 |
1件: Proteasome |
13件: 11, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 288, 331 |
35 |
Bortezomib (velcade®) |
Bortezomib |
D03150 |
1件: PSMB5 |
1件: Proteasome |
1件: 66 |
36 |
Budesonide |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
9件: 66, 93, 94, 95, 96, 97, 98, 228, 299 |
37 |
Calcitriol |
Calcitriol |
D00129 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
8件: 37, 46, 49, 66, 96, 158, 235, 326 |
38 |
Ccx168 |
- |
- |
- |
- |
6件: 43, 44, 66, 109, 222, 223 |
39 |
Cemdisiran |
- |
- |
- |
- |
2件: 66, 109 |
40 |
Chinese herb prescription granule plus prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 66 |
41 |
Cilazapril |
Cilazapril |
D01069, D07699 |
1件: ACE |
4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
1件: 66 |
42 |
Corticosteroid |
- |
- |
- |
- |
10件: 13, 42, 43, 44, 45, 66, 84, 96, 97, 222 |
43 |
Corticotherapy |
- |
- |
- |
- |
1件: 66 |
44 |
Cyclophosphamid |
Cyclophosphamide |
D00287, D07760 |
- |
- |
1件: 66 |
45 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
46 |
Dipyridamole |
Dipyridamole |
D00302 |
2件: PDE4A, PDE5A |
6件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 46, 49, 51, 66, 224 |
47 |
Enalapril |
Enalapril |
D00621, D07892 |
1件: ACE |
4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
4件: 19, 46, 66, 113 |
48 |
Enalapril valsartan methylprednisone |
Methylprednisone |
- |
- |
- |
1件: 66 |
49 |
Fecal microbiota transplantation |
- |
- |
- |
- |
5件: 2, 66, 94, 96, 97 |
50 |
Fish oil |
Fish oil |
- |
- |
- |
7件: 13, 46, 49, 66, 96, 260, 299 |
51 |
Fostamatinib |
Fostamatinib |
D09347 |
1件: SYK |
15件: B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis |
4件: 46, 49, 61, 66 |
52 |
Fostamatinib 100 mg |
Fostamatinib |
D09347 |
1件: SYK |
15件: B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis |
1件: 66 |
53 |
Fostamatinib 150 mg |
Fostamatinib |
D09347 |
1件: SYK |
15件: B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis |
1件: 66 |
54 |
Fostamatinib disodium tablet 100 mg |
Fostamatinib |
D09347 |
1件: SYK |
15件: B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis |
1件: 66 |
55 |
Fostamatinib disodium tablet 150 mg |
Fostamatinib |
D09347 |
1件: SYK |
15件: B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis |
1件: 66 |
56 |
Gastrus |
- |
- |
- |
- |
1件: 66 |
57 |
Hormone (prednisone) |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 66 |
58 |
Human soluble recombinant fc-gamma receptor iib |
- |
- |
- |
- |
1件: 66 |
59 |
Hydroxychloroquine |
Hydroxychloroquine |
D08050 |
- |
- |
18件: 13, 41, 46, 48, 49, 53, 56, 66, 84, 89, 90, 96, 222, 234, 254, 271, 298, 299 |
60 |
Hydroxychloroquine sulfate |
Hydroxychloroquine |
D08050 |
- |
- |
2件: 46, 66 |
61 |
Immunosuppressive agents |
- |
- |
- |
- |
2件: 50, 66 |
62 |
Immunosuppressive treatment |
- |
- |
- |
- |
1件: 66 |
63 |
Inhibace/cozaar |
- |
- |
- |
- |
1件: 66 |
64 |
Intravenous rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 66 |
65 |
Ionis-fb-lrx |
- |
- |
- |
- |
1件: 66 |
66 |
Irbesartan |
Irbesartan |
D00523 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
4件: 66, 167, 168, 222 |
67 |
Irbesartan tablets |
Irbesartan |
D00523 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 66, 222 |
68 |
Irbesartan tablets (approved in the usa. reference listed drug avapro) ndc # 43547-0374-03 |
Irbesartan |
D00523 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 66, 222 |
69 |
Leflunomide |
Leflunomide |
D00749 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
9件: 11, 40, 46, 49, 53, 66, 224, 271, 300 |
70 |
Leflunomide 20 mg+prednisone 0.5mg/kg/d |
Leflunomide |
D00749 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
1件: 66 |
71 |
Lisinopril |
Lisinopril |
D00362, D08131 |
1件: ACE |
4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
5件: 46, 66, 67, 113, 222 |
72 |
Lnp023 |
- |
- |
- |
- |
3件: 62, 66, 222 |
73 |
Losartan |
Losartan |
D00357, D08146 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
18件: 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
74 |
Low antigen content diet |
- |
- |
- |
- |
1件: 66 |
75 |
Menatetrenone |
Menatetrenone |
D00100 |
- |
- |
1件: 66 |
76 |
Methylprednisolon |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
4件: 13, 51, 66, 222 |
77 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
78 |
Methylprednisolone (mp) or prednisone (pred) |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 66 |
79 |
Methylprednisolone mylan générique |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 66 |
80 |
Methylprednisolone pulse |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 66, 220 |
81 |
Methylprednisolone(intravenously in the 1st-2nd-3rd month ) |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 66 |
82 |
Methylprednisolone(intravenously in the 1st-3rd-5th month) |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 66 |
83 |
Methylprednisone |
Methylprednisone |
- |
- |
- |
3件: 46, 66, 222 |
84 |
Mizoribine |
Mizoribine |
D01392 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
7件: 49, 51, 53, 66, 94, 222, 224 |
85 |
Multi-glycoside of tripterygium wilfordii hook. f. (twh) |
Tripterygium wilfordii whole |
- |
- |
- |
1件: 66 |
86 |
Mycophenolate |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
33件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
87 |
Mycophenolate mofetil |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
88 |
Mycophenolate mofetil (mmf) |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
4件: 49, 60, 66, 222 |
89 |
Mycophenolate mofetil plus lower dose of prednisone |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
1件: 66 |
90 |
Mycophenolate sodium |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
3件: 53, 66, 222 |
91 |
Mycophenolic acid |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
7件: 11, 49, 51, 60, 66, 96, 222 |
92 |
Mycophenolic sodium |
- |
- |
- |
- |
2件: 66, 222 |
93 |
Myfortic |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
4件: 49, 66, 222, 228 |
94 |
Myfortic 180mg tablets |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 66, 222 |
95 |
Myfortic 360mg tablets |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 66, 222 |
96 |
Nefecon |
- |
- |
- |
- |
1件: 66 |
97 |
Omega-3 |
Omega-3 fatty acids |
- |
- |
- |
7件: 13, 46, 49, 66, 79, 96, 299 |
98 |
Omega-3 fatty acid |
Omega-3 fatty acids |
- |
- |
- |
2件: 46, 66 |
99 |
Omega-3 fatty acid ethylester90 |
Omega-3 fatty acids |
- |
- |
- |
1件: 66 |
100 |
Omega-3 fatty acid fish oil supplement |
Fish oil |
- |
- |
- |
1件: 66 |
101 |
Oms721 |
- |
- |
- |
- |
5件: 64, 66, 109, 222, 223 |
102 |
Opl-ccl2-lpm |
- |
- |
- |
- |
1件: 66 |
103 |
Over-encapsulated 150 mg irbesartan tablets |
Irbesartan |
D00523 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 66 |
104 |
Over-encapsulated irbesartan tablets |
Irbesartan |
D00523 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 66, 222 |
105 |
Paricalcitol |
Paricalcitol |
D00930 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
3件: 19, 66, 218 |
106 |
Placebo |
- |
- |
- |
- |
20件: 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
107 |
Potassium |
Potassium |
D08403 |
- |
- |
9件: 46, 66, 67, 98, 115, 167, 179, 215, 235 |
108 |
Prednisolon |
- |
- |
- |
- |
4件: 46, 66, 96, 97 |
109 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
110 |
Prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
43件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
111 |
Prednisone + inhibace/cozaar |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 66 |
112 |
Prednisone 5 mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 46, 66 |
113 |
Prednisone alone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 11, 66 |
114 |
Prednisone and cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
1件: 66 |
115 |
Prednisone arrow 20mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 66 |
116 |
Prednisone arrow 5 mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 66 |
117 |
Prednisone in full dose |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 66 |
118 |
Prednisone or prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 66 |
119 |
Prednisone plus cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
1件: 66 |
120 |
Probucol |
Probucol |
D00476 |
- |
- |
1件: 66 |
121 |
Protectis |
- |
- |
- |
- |
1件: 66 |
122 |
Ramipril |
Ramipril |
D00421 |
1件: ACE |
4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
7件: 46, 49, 66, 67, 113, 218, 257 |
123 |
Rapamune |
Sirolimus |
D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
5件: 2, 60, 66, 67, 158 |
124 |
Re-021 |
- |
- |
- |
- |
2件: 66, 222 |
125 |
Reh-acteoside |
Acteoside |
- |
- |
- |
1件: 66 |
126 |
Renin angiotensin system (ras) blockade |
Angiotensin ii |
D00150, D02014 |
2件: AGTR1, AGTR2 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 66 |
127 |
Risedronate |
Risedronic acid |
D00942, D03234, D08484 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
5件: 46, 66, 96, 113, 274 |
128 |
Rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
129 |
Simulect |
Basiliximab |
D03058 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
2件: 66, 97 |
130 |
Simvastatin |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
131 |
Sirolimus |
Sirolimus |
D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
30件: 13, 17, 34, 35, 36, 46, 51, 60, 62, 63, 65, 66, 67, 85, 89, 96, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 |
132 |
Sm101 |
- |
- |
- |
- |
3件: 49, 63, 66 |
133 |
Sparsentan |
Sparsentan |
- |
- |
- |
2件: 66, 222 |
134 |
Steroids |
- |
- |
- |
- |
7件: 46, 50, 51, 63, 66, 96, 97 |
135 |
Steroids plus azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 66 |
136 |
Sulfate |
Sulfate ion |
- |
- |
- |
22件: 2, 6, 11, 13, 26, 34, 36, 46, 49, 60, 61, 64, 66, 79, 86, 96, 222, 226, 265, 296, 297, 299 |
137 |
Supportive and immunosuppressive therapy |
- |
- |
- |
- |
1件: 66 |
138 |
Supportive therapy |
- |
- |
- |
- |
1件: 66 |
139 |
Supportive therapy with: ace-inhibitor / arb / statin |
- |
- |
- |
- |
1件: 66 |
140 |
Tacrolimus |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
29件: 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
141 |
Tailored diet |
- |
- |
- |
- |
1件: 66 |
142 |
Telmisartan |
Telmisartan |
D00627 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 66, 67 |
143 |
The yi-qi-qing-jie herbal compound |
- |
- |
- |
- |
1件: 66 |
144 |
Tripterygium |
Tripterygium wilfordii whole |
- |
- |
- |
8件: 46, 66, 67, 96, 162, 222, 224, 271 |
145 |
Tripterygium wilfordii |
Tripterygium wilfordii whole |
- |
- |
- |
6件: 46, 66, 67, 222, 224, 271 |
146 |
Tripterygium wilfordii (tw) |
Tripterygium wilfordii whole |
- |
- |
- |
2件: 66, 222 |
147 |
Valsartan |
Valsartan |
D00400 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
6件: 57, 58, 66, 75, 218, 222 |
148 |
Vis649 |
- |
- |
- |
- |
1件: 66 |
149 |
Warfarin |
Warfarin |
D00564, D01280, D08682 |
2件: NQO1, VKORC1 |
5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
10件: 6, 8, 13, 19, 46, 49, 66, 85, 88, 96 |
150 |
Wm (shentong granules) |
- |
- |
- |
- |
1件: 66 |
151 |
lnp023 hydrochloride salt |
- |
- |
- |
- |
2件: 62, 66 |